Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)

• Status: Terminated
• Trial end date: 2015-11-17
• Target enrollment: 0
• Participant gender: All

Summary

To study the effect of olmesartan on walking distance and quality of life in peripheral artery disease patients with hypertension treated For intermittent claudication.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Antihypertensive Agents; Olmesartan; Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• Aged between 20 and 85 years at visit 1

• Patients with ankle-brachial index (ABI) of less than 0.9 in one or both legs with history of intermittent claudication stable for the previous 6 months

• Patients whose statins, anti hypertensive medications and antiplatelet medications are stable for the past 6 months. Statins and cilostazol are allowed but needs to be stable for the past 6 months (diabetic medications may be changed)

• Patients whose blood pressure is more than 140/90 mmHg with/without anti-hypertension treatment

Exclusion Criteria:

• Blood pressure of more than 180/110 mmHg

• Patients taking ARBs or ACE inhibitors treatment for at least 6 months before

• Patients taking aldosterone receptor antagonists at least 6 months before

• Patients with serum creatinine of more than 3 mg/dL

• serum potassium (K+) > 5.5mg/dl

• History of bilateral renal artery stenosis

• History of acute coronary syndrome or heart failure hospitalization within 6 months

• Peripheral arterial revascularization planned within 1 month

• Critical limb ischemia

• Patients with impaired cognition (e.g. dementia)

• pregnancy or women at age of childbearing potential